CORPORATE INTEGRITY AGREEMENT
BETWEEN THE
OFFICE OF INSPECTOR GENERAL
OF THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AND
NASON MEDICAL CENTER

I. PREAMBLE

Nason Medical Center, LLC, and Bankfield Holding Company, LLC, (collectively referred to as “Nason”) hereby enter into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements).

Contemporaneously with this CIA, Nason is entering into a Settlement Agreement with the United States.

Nason is a wholly owned subsidiary of Bankfield Holding Company, LLC (Bankfield).

Prior to entering into this CIA, Nason removed all imaging equipment from its buildings, except x-ray machines, and stopped billing for imaging services. In addition, Nason took down signage identifying Nason as a site for emergency medical services, and began ceasing all advertising of Nason as a provider of emergency services.

II. TERM AND SCOPE OF THE CIA

A. The period of the compliance obligations assumed by Nason under this CIA shall be five years from the effective date of this CIA. The “Effective Date” shall be the date on which the final signatory of this CIA executes this CIA. Each one-year period, beginning with the one-year period following the Effective Date, shall be referred to as a “Reporting Period.”

B. Sections VII, X, and XI shall expire no later than 120 days after OIG’s receipt of: (1) Nason’s final annual report; or (2) any additional materials submitted by Nason pursuant to OIG’s request, whichever is later.
C. The scope of this CIA shall be governed by the following definitions:

1. "Covered Persons" includes:
   a. all owners, officers, directors, "Managers" (Members of the "Management Committee") and employees of Nason.
   b. all contractors, subcontractors, agents, and other persons who provide patient care items or services or who perform billing or coding functions on behalf of Nason, excluding vendors whose sole connection with Nason is selling or otherwise providing medical supplies or equipment to Nason and who do not bill the Federal health care programs for such medical supplies or equipment; and
   c. all physicians and other non-physician practitioners who work within one or more of Nason's facilities.

   Notwithstanding the above, this term does not include part-time or per diem employees, contractors, subcontractors, agents, and other persons who are not reasonably expected to work more than 160 hours during a Reporting Period, except that any such individuals shall become "Covered Persons" at the point when they work more than 160 hours during a Reporting Period.

2. "Relevant Covered Persons" includes Covered Persons involved in the delivery of patient care items or services and/or in the preparation or submission of claims for reimbursement from any Federal health care program.

III. CORPORATE INTEGRITY OBLIGATIONS

Nason shall establish and maintain a Compliance Program that includes the following elements:

A. Compliance Officer and Committee

1. Compliance Officer. Within 90 days after the Effective Date, Nason shall appoint a Covered Person to serve as its Compliance Officer and shall maintain a Compliance Officer for the term of the CIA. The Compliance Officer shall be a member of senior management of Nason, shall report directly to the Chief Executive Officer of Nason Medical Center CIA.
Nason, and shall not be or be subordinate to the General Counsel or Chief Financial Officer or have any responsibilities that involve acting in any capacity as legal counsel or supervising legal counsel functions for Nason. The Compliance Officer will visit each location where Nason provides patient services at least once every two weeks. The Compliance Officer shall be responsible for, without limitation:

a. developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with Federal health care program requirements;

b. making periodic (at least quarterly) reports regarding compliance matters directly to the “Management Committee” (Bankfield’s governing body), and shall be authorized to report on such matters to the “Management Committee” at any time. Written documentation of the Compliance Officer’s reports to the “Management Committee” shall be made available to OIG upon request; and

c. monitoring the day-to-day compliance activities engaged in by Nason as well as for any reporting obligations created under this CIA.

Any noncompliance job responsibilities of the Compliance Officer shall be limited and must not interfere with the Compliance Officer’s ability to perform the duties outlined in this CIA.

Nason shall report to OIG, in writing, any changes in the identity or position description of the Compliance Officer, or any actions or changes that would affect the Compliance Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within five days after such a change.

2. **Compliance Committee.** Within 90 days after the Effective Date, Nason shall appoint a Compliance Committee. The Compliance Committee shall, at a minimum, include the Compliance Officer and other members of senior management necessary to meet the requirements of this CIA (e.g., senior executives of relevant departments, such as billing, clinical, human resources, audit, and operations, as well at least one employee who works at least 20 hours per week at each building where Nason sees patients). The Compliance Officer shall chair the Compliance Committee and the Nason Medical Center CIA.
Committee shall support the Compliance Officer in fulfilling his/her responsibilities (e.g., shall assist in the analysis of Nason’s risk areas and shall oversee monitoring of internal and external audits and investigations). The Compliance Committee shall meet at least quarterly. The minutes of the Compliance Committee meetings shall be made available to OIG upon request.

Nason shall report to OIG, in writing, any changes in the composition of the Compliance Committee, or any actions or changes that would affect the Compliance Committee’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.

3. "Management Committee’s” Compliance Obligations. The "Management Committee” of Nason shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The “Management Committee” must include at least one independent (i.e., non-executive, who is neither an employee nor owner of Nason) member.

The “Management Committee” shall, at a minimum, be responsible for the following:

a. meeting at least quarterly to review and oversee Nason's Compliance Program, including but not limited to the performance of the Compliance Officer and Compliance Committee;

b. submitting to the OIG a description of the documents and other materials it reviewed, as well as any additional steps taken, in its oversight of the compliance program and in support of making the resolution below during each Reporting Period; and

c. for each Reporting Period of the CIA, adopting a resolution, signed by each “Manager” of the “Management Committee” summarizing its review and oversight of Nason’s compliance with Federal health care program requirements and the obligations of this CIA.

At minimum, the resolution shall include the following language:

Nason Medical Center CIA
“The Management Committee” has made a reasonable inquiry into the operations of Nason’s Compliance Program including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the “Management Committee” has concluded that, to the best of its knowledge, Nason has implemented an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.

If the “Management Committee” is unable to provide such a conclusion in the resolution, the “Management Committee” shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at Nason.

Nason shall report to OIG, in writing, any changes in the composition of the “Management Committee”, or any actions or changes that would affect the “Management Committee’s” ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.

4. Management Certifications. In addition to the responsibilities set forth in this CIA for all Covered Persons, certain Nason employees (Certifying Employees) are specifically expected to monitor and oversee activities within their areas of authority and shall annually certify that the applicable Nason department is in compliance with applicable Federal health care program requirements and with the obligations of this CIA. These Certifying Employees shall include all employees with management responsibilities. Such employees include, but are not limited to, the following positions: the Billing Manager; Director of Human Resources; Medical Director; Nason Medical Center Manager and CEO; Laboratory Director; Radiology Director; Business Administration Manager; Accounting Director; Director of Business Analysis; and Bankfield CEO. For each Reporting Period, each Certifying Employee shall sign a certification that states:

“I have been trained on and understand the compliance requirements and responsibilities as they relate to [insert name of department, and/or facility], an area under my supervision. My job responsibilities include ensuring compliance with regard to the [insert name of department, and/or facility] with all applicable Federal health care program requirements, obligations of the Corporate Integrity Agreement, and Nason policies, and I have taken steps to promote such compliance. To the best of my knowledge, except as otherwise described herein, the [insert name of department] of Nason is in

Nason Medical Center CIA
compliance with all applicable Federal health care program requirements and the obligations of the Corporate Integrity Agreement. I understand that this certification is being provided to and relied upon by the United States.”

If any Certifying Employee is unable to provide such a certification, the Certifying Employee shall provide a written explanation of the reasons why he or she is unable to provide the certification outlined above.

B. **Written Standards**

1. **Code of Conduct.** Within 90 days after the Effective Date, Nason shall develop, implement, and distribute a written Code of Conduct to all Covered Persons. Nason shall make the performance of job responsibilities in a manner consistent with the Code of Conduct an element in evaluating the performance of all employees. The Code of Conduct shall, at a minimum, set forth:

   a. Nason’s commitment to full compliance with all Federal health care program requirements, including its commitment to prepare and submit accurate claims consistent with such requirements;

   b. Nason’s requirement that all of its Covered Persons shall be expected to comply with all Federal health care program requirements and with Nason’s own Policies and Procedures;

   c. the requirement that all of Nason’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by Nason, suspected violations of any Federal health care program requirements or of Nason’s own Policies and Procedures; and

   d. the right of all individuals to use the Disclosure Program described in Section III.H, and Nason’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures.

Within 90 days after the Effective Date, Nason shall distribute the Code of Conduct to all Covered Persons. Nason shall review the Code of Conduct at least annually to determine if revisions are appropriate and shall make any necessary revisions.
based on such review. The Code of Conduct shall be distributed at least annually to all Covered Persons.

2. Policies and Procedures. Within 90 days after the Effective Date, Nason shall develop and implement written Policies and Procedures regarding the operation of its compliance program, including the compliance program requirements outlined in this CIA and Provider's compliance with Federal health care program requirements. Throughout the term of this CIA, Nason shall enforce and comply with its Policies and Procedures and shall make such compliance an element of evaluating the performance of all employees.

At a minimum, the Policies and Procedures shall address:

a. the subjects relating to the Code of Conduct identified in Section III.B.1;

b. billing and reimbursement: these Policies and Procedures shall be designed to ensure Nason complies with all Federal health care program requirements on billing and reimbursement, including:

   i. ensuring proper and accurate submission of claims and cost reports to Federal health care programs; and

   ii. ensuring the proper and accurate documentation of business/medical records.

c. Documentation of medical records: these Policies and Procedures shall be designed to ensure Nason complies with Federal health care program requirements applicable to the documentation of business/medical records:

   i. ensuring proper and accurate documentation in the billing, coding and reimbursement process;

   ii. the personal obligation of each individual involved in the business/medical documentation process to ensure that such documentation is accurate;

Nason Medical Center CIA

7
iii. the legal sanctions for violation of the Federal health care program requirements; and

iv. examples of proper and improper medical documentation practices.

d. requirements related to Nason’s advertising as described in Section III.D.

e. requirements related to appropriate testing as described in Section III.D.

f. requirements that Nason provide services only as an Urgent Care Center as described in Section III.D.

Within 90 days after the Effective Date, the Policies and Procedures shall be distributed to all Covered Persons. Appropriate and knowledgeable staff shall be available to explain the Policies and Procedures.

At least annually (and more frequently, if appropriate), Nason shall assess and update, as necessary, the Policies and Procedures. Within 30 days after the effective date of any revisions or addition of new Policies and Procedures, a description of the revisions shall be communicated to all affected Covered Persons and any revised or new Policies and Procedures shall be made available to all Covered Persons.

C. Training and Education

1. Training Plan. Within 90 days after the Effective Date, Nason shall develop a written plan (Training Plan) that outlines the steps Nason will take to ensure that: (a) all Covered Persons receive adequate training regarding Nason’s CIA requirements and Compliance Program, including the Code of Conduct and (b) all Relevant Covered Persons receive adequate training regarding: (i) the Federal health care program requirements regarding the accurate coding and submission of claims; (ii) policies, procedures, and other requirements applicable to the documentation of medical records; (iii) the personal obligation of each individual involved in the claims submission process to ensure that such claims are accurate; (iv) applicable reimbursement statutes, regulations, and program requirements and directives; (v) the legal sanctions for violations of the Federal health care program requirements; (vi) examples of proper and improper claims submission practices; and (vii) the obligation of each individual

Nason Medical Center CIA
involved in ensuring the complete compliance with the requirements of Section III.D and complying with related policies and procedures.

The Training Plan shall include information regarding the training topics, the categories of Covered Persons and Relevant Covered Persons required to attend each training session, the length of the training, the schedule for training, and the format of the training. Within 30 days of the OIG’s receipt of Nason’s Training Plan, OIG will notify Nason of any comments or objections to the Training Plan. Absent notification by the OIG that the Training Plan is unacceptable, Nason may implement its Training Plan. Nason shall furnish training to its Covered Persons and Relevant Covered Persons pursuant to the Training Plan during each Reporting Period.

2. **Coder Certification.** Within 120 days after the Effective Date, Nason will establish requirements for personnel who code and will maintain those requirements, as described in this paragraph, for the term of the CIA. In addition to receiving the Training described above, each coding professional shall attain a nationally recognized billing and coding certification within 120 days of the Effective Date.

3. **“Management Committee” Member Training.** Within 90 days after the Effective Date, Nason shall provide at least two hours of training to each member of the “Management Committee.” This training shall address the Nason’s CIA requirements and Compliance Program (including the Code of Conduct), the corporate governance responsibilities of “Management Committee” members, and the responsibilities of “Management Committee” members with respect to review and oversight of the Compliance Program. Specifically, the training shall address the unique responsibilities of health care “Management Committee” members, including the risks, oversight areas, and strategic approaches to conducting oversight of a health care entity. This training may be conducted by an outside compliance expert hired by the “Management Committee” and should include a discussion of the OIG’s guidance on Board of Director member responsibilities.

   New members of the “Management Committee” shall receive the “Management Committee” Member Training described above within 30 days after becoming a member or within 90 days after the Effective Date, whichever is later.

4. **Certification.** Each individual who is required to attend training shall certify, in writing or in electronic form, that he or she has received the required training. The certification shall specify the type of training received and the date

Nason Medical Center CIA
received. The Compliance Officer (or designee) shall retain the certifications, along with all course materials.

5. **Qualifications of Trainer.** Persons providing the training shall be knowledgeable about the subject area.

6. **Update of Training Plan.** Nason shall review the Training Plan annually, and, where appropriate, update the Training Plan to reflect changes in Federal health care program requirements, any issues discovered during internal audits or the Claims Review, and any other relevant information. Any updates to the Training Plan must be reviewed and approved by the OIG prior to the implementation of the revised Training Plan. Within 30 days of OIG’s receipt of any updates or revisions to Nason’s Training Plan, OIG will notify Nason of any comments or objections to the revised Training Plan. Absent notification from the OIG that the revised Training Plan is unacceptable, Nason may implement the revised Training Plan.

7. **Computer-based Training.** Nason may provide the training required under this CIA through appropriate computer-based training approaches. If Nason chooses to provide computer-based training, it shall make available appropriately qualified and knowledgeable staff or trainers to answer questions or provide additional information to the individuals receiving such training.

D. **Nason agrees to advertise and provide services only appropriate for an Urgent Care Center**

1. **No representations that Nason provides medical care for emergencies.** Nason agrees not to advertise itself, in any manner, as a provider of emergency services. This includes no signage or references (orally, in writing, in photos or in any other form) that Nason provides emergency services or that individuals should seek any emergency services at Nason. Nason must not advertise, display or exhibit any signs or symbols that would identify its services as including emergency medical services. Nason may not reference emergency care/emergency services on its business cards, in its brochures, on its website, in any advertising or in any other manner. Nason may not compare itself to emergency departments or use the words “emergency,” “emergency room,” “emergency care,” “emergency medicine,” “emergency department” or any other words suggesting the meaning of these words/phrases in referring to any

Nason Medical Center CIA
aspect of its business or the services it provides. This includes a prohibition on advertising of any conditions, diagnoses or treatment that could represent an emergency medical condition.

2. **No provision of imaging services, except x-rays.** Nason agrees to remove all imaging equipment (except x-ray machines) from its premises and not to bill for any imaging services, except appropriate use of x-rays.

3. **Nason agrees to provide services consistent only with being an Urgent Care Center.** Nason is not licensed to provide Emergency Care. It is not a freestanding emergency service under South Carolina law and will not provide emergency services, or advertise or represent that it provides emergency services. Nason shall only provide appropriate services to patients consistent with their presenting at an Urgent Care Center.

E. **Independent Monitor**

Within 60 days after the Effective Date, Nason shall retain an appropriately qualified monitor (the “Monitor”), selected by OIG after consultation with Nason. The Monitor may retain additional personnel, including, but not limited to, independent consultants, if needed to help meet the Monitor’s obligations under this CIA. The Monitor may confer and correspond with Nason or OIG individually or together. The Monitor and Nason shall not negotiate or enter into a financial relationship, other than the monitoring engagement required by this section, until after the date of OIG’s CIA closure letter to Nason or six months after the expiration of this CIA, whichever is later.

The Monitor is not an agent of OIG. However, the Monitor may be removed by OIG at its sole discretion. If the Monitor resigns or is removed for any other reasons prior to the termination of the CIA, Nason shall retain, within 60 days of the resignation or removal, another Monitor selected by OIG, with the same functions and authorities.

Within 30 days after Nason retains the Monitor, the Monitor shall develop a workplan will be used in the performance of its reviews of Nason under the CIA, and provide such audit workplan to the OIG for review. The Monitor may, in its discretion and in consultation with the OIG, modify the audit workplan throughout the term of the CIA, based upon the Monitor’s findings and observations in the performance of the CIA reviews.

Nason Medical Center CIA
1. **Scope of Review.** The Monitor shall be responsible for assessing the effectiveness, reliability, and thoroughness of the following:

a. Training, including, but not limited to:
   
i. whether the training programs required under Section III.C are effective, thorough, and competency-based.

b. Nason’s internal compliance-related systems and processes, including but not limited to:
   
i. whether the systems in place to promote compliance with the provisions of this CIA and with the requirements of the Federal health care programs and to respond to compliance issues are operating in a timely and effective manner; and
   
ii. whether Nason’s communication systems are effective, allowing for accurate information, decisions, and results of decisions to be transmitted to the proper individuals in a timely fashion.

c. Nason’s response to compliance issues, which shall include an assessment of:

   Nason’s implementation and enforcement of policies and procedures to identify, investigate, and follow up on compliance issues, including:
   
i. Nason’s ability to determine the scope of the issue, including, but not limited to, whether the issue is isolated or systemic;
   
ii. Nason’s ability to conduct a root cause analysis;
   
iii. Nason’s ability to create an action plan to respond to the problem;
iv. Nason’s ability to execute the action plan; and

v. Nason’s ability to monitor and evaluate whether the assessment, action plan, and execution of that plan was effective, reliable, and thorough.

d. Nason’s efforts to ensure that each patient who presents for care receives such care in accordance with:

i. professionally recognized standards of health care, consistent with being an Urgent Care Center;

ii. State and local statutes, regulation, and other directives or guidelines; and

iii. Nason’s Policies and Procedures, including those implemented under Section III.B of this CIA.

e. Nason’s representations of its services as Urgent Care services and not for emergencies, as described in section III.D.

f. Nason’s limitation of its imaging services to appropriate use of X-ray’s only, as described in section III.D.

g. Nason’s provision of services consistent with its designation as an Urgent Care Center only, as described in section III.D, and

h. whether Nason’s systems in place promote quality of care and respond to quality of care issues and are operating in a timely and effective manner.

2. Access. The Monitor shall have:

a. immediate access to Nason, at any time and without prior notice, to assess compliance with this CIA, to assess the effectiveness of the internal quality assurance mechanisms, and to ensure that the data being generated is accurate;
b. immediate access to:

i. internal or external reports;

ii. Disclosure Program complaints;

iii. patient satisfaction surveys;

iv. reports of an incident that required hospitalization or emergency room treatment;

v. patient records;

vi. documents in the possession or control of any quality committee, peer review committee, medical review committee, or other such committee;

vii. any other data in the format the Monitor determines relevant to fulfilling the duties required under this CIA; and

viii. immediate access to patients, and Covered Persons for interviews outside the presence of Nason supervisory staff or counsel, provided such interviews are conducted in accordance with all applicable laws and the rights of such individuals. The Monitor shall give full consideration to an individual’s clinical condition before interviewing a patient.

3. **Baseline Systems Assessment.** Within 60 days after the Monitor is retained by Nason or 120 days after the Effective Date of the CIA, whichever is later, the Monitor shall:

a. complete an assessment of the effectiveness, reliability, scope, and thoroughness of Nason’s compliance systems, including, but not limited to, those described in Section III.E. of the CIA;
b. in conducting this assessment, visit all of Nason’s facilities and, at a minimum, observe corporate compliance meetings, observe “Management Committee’s” meetings, interview key employees, review relevant documents, and observe patient care; and

c. submit a written report to Nason and OIG that sets forth, at a minimum:

i. a summary of the Monitor’s activities in conducting the assessment;

ii. the Monitor’s findings regarding the effectiveness, reliability, scope, and thoroughness of each of the requirements/systems, including, but not limited to, those described in Section III.E; and

iii. the Monitor’s recommendations to Nason as to how to improve the effectiveness, reliability, scope, and thoroughness of the requirements/systems, including, but not limited to, those described in Section III.E.

4. **Systems Improvements Assessments.** On a semi-annual basis, the Monitor shall:

a. assess the effectiveness, reliability, and thoroughness of Nason’s compliance systems, including, but not limited to, those described in Section III.E.1. of the CIA

b. after the first Systems Improvements Assessment, assess Nason’s response to recommendations made in prior written assessment reports;

c. in conducting these assessments, visit all of Nason’s facilities and, at a minimum, observe corporate compliance meetings, observe “Management Committee” meetings, interview key employees, review relevant documents, and observe patient care (the Monitor may also want to have regular telephone calls with Nason and any of its facilities); and

Nason Medical Center CIA
d. submit a written report to Nason and OIG that sets forth, at a minimum:

i. a summary of the Monitor’s activities in conducting the assessment;

ii. the Monitor’s findings regarding the effectiveness, reliability, scope, and thoroughness of Nason’s compliance systems, including, but not limited to, those described in Section III.E.1 of the CIA;

iii. the Monitor’s recommendations to Nason as to how to improve the effectiveness, reliability, scope, and thoroughness of the Nason’s compliance systems, including, but not limited to, those described in Section III.E.1 of the CIA; and

iv. the Monitor’s assessment of Nason’s response to the Monitor’s prior recommendations.

For the first Reporting Period, the assessment shall be based on the portion of the Reporting Period that was not covered in the Baseline Systems Improvement Assessment. For each subsequent Reporting Period, one assessment shall be based on the first six months of the Reporting Period and the other assessment shall be based on the second six months of the Reporting Period. The Monitor shall submit written reports of the Systems Improvement Assessments no later than 30 days after the end of the relevant six-month period to Provider and OIG.

5. Financial Obligations of Nason and the Monitor.

a. Nason shall be responsible for all reasonable costs incurred by the Monitor in connection with this engagement, including, but not limited to, labor costs (direct and indirect); consultant and subcontract costs; materials cost (direct and indirect); and other direct costs (travel, other miscellaneous).

b. Nason shall pay the Monitor’s bills within 30 days of receipt. Failure to pay the Monitor within 30 calendar days of receipt

Nason Medical Center CIA
of the Monitor’s invoice for services previously rendered shall constitute a basis to impose stipulated penalties or exclude Nason, as provided under Section X of the CIA. While Nason must pay all of the Monitor’s bills within 30 days, Nason may bring any disputed Monitor’s Costs or bills to OIG’s attention.

c. The Monitor shall charge a reasonable amount for its fees and expenses, and shall submit monthly invoices to Nason with a reasonable level of detail reflecting all key category costs billed.

d. The Monitor shall submit a written report for each Reporting Period representing an accounting of its costs throughout the year to Nason and to OIG by the submission deadline of Nason’s Annual Report. This report shall reflect, on a cumulative basis, all key category costs included on monthly invoices.

6. Additional Nason Obligations. Nason shall:

a. within 30 days after receipt of each written report of the Baseline Systems Assessment or Systems Improvement Assessments, submit a written response to OIG and the Monitor to each recommendation contained in those reports stating what action Nason took in response to each recommendation or why Nason has elected not to take action based on the recommendation;

b. provide to its Compliance Committee and “Management Committee” copies of all documents and reports provided to the Monitor;

c. ensure the Monitor’s immediate access to the facility, patients, Covered Persons, and documents, and assist in obtaining full cooperation by its current employees, contractors, and agents;
d. provide access to current patients and provide contact information for their families and guardians consistent with the rights of such individuals under state or federal law, and not impede their cooperation with the Monitor;

e. assist in locating and, if requested, attempt to obtain cooperation from past employees, contractors, agents, and patients and their families;

f. provide the last known contact information for former patients, their families, or guardians consistent with the rights of such individuals under state or federal law, and not impede their cooperation; and

g. not sue or otherwise bring any action against the Monitor related to any findings made by the Monitor or related to any exclusion or other sanction of Nason under this CIA; provided, however, that this clause shall not apply to any suit or other action based solely on the dishonest or illegal acts of the Monitor, whether acting alone or in collusion with others.

7. Additional Monitor Obligations. The Monitor shall:

a. abide by all state and federal laws and regulations concerning the privacy, dignity, and employee rights of all Covered Persons, and patients;

b. abide by the legal requirements of Nason to maintain the confidentiality of each patient’s personal and clinical records. Nothing in this subsection, however, shall limit or affect the Monitor’s obligation to provide information, including information from patient clinical records, to OIG, and, when legally or professionally required, to other agencies;

c. at all times act reasonably in connection with its duties under the CIA including when requesting information from Nason;
d. where independently required to do so by applicable law or professional licensing standards, report any finding to an appropriate regulatory or law enforcement authority, and simultaneously submit copies of such reports to OIG and to Nason;

e. not be bound by any other private or governmental agency’s findings or conclusions. Nothing in the previous sentence, however, shall preclude OIG or Nason from using any material generated by the Monitor, or any opinions, testimony, or conclusions from the Monitor in any action under the CIA or pursuant to any other OIG authorities or in any other situations not explicitly excluded in this subsection;

f. abide by the provisions of the Health Insurance Portability and Accountability Act (HIPAA) of 1996 to the extent required by law including, without limitation, entering into a business associate agreement with Nason; and

g. except to the extent required by law, maintain the confidentiality of any proprietary financial and operational information, processes, procedures, and forms obtained in connection with its duties under this CIA and not comment publicly concerning its findings except to the extent authorized by OIG.

F. Review Procedures

1. General Description

a. Engagement of Independent Review Organization. Within 90 days after the Effective Date, Nason shall also engage an entity, (or entities), such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform the reviews listed in this Section III.F. The applicable requirements relating to the IRO are outlined in Appendix A to this CIA, which is incorporated by reference.
b. **Retention of Records.** The IRQ and Nason shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRQ and Nason) related to the reviews.

2. **Claims Review.** The IRQ shall review Nason’s coding, billing, and claims submission to the Medicare and state Medicaid programs and the reimbursement received (Claims Review) and shall prepare a Claims Review Report, as outlined in Appendix B to this CIA, which is incorporated by reference.

3. **Validation Review.** In the event OIG has reason to believe that: (a) Nason’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Nason shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Nason’s final Annual Report shall be initiated no later than one year after Nason’s final submission (as described in Section II) is received by OIG.

Prior to initiating a Validation Review, OIG shall notify Nason of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Nason may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Nason agrees to provide any additional information as may be requested by OIG under this Section III.F.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Nason prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

4. **Independence and Objectivity Certification.** The IRO shall include in its report(s) to Nason a certification that the IRO has (a) evaluated its professional independence and objectivity with respect to the reviews conducted under this Section III.F and (b) concluded that it is, in fact, independent and objective, in accordance with the requirements specified in Appendix A to this CIA.

Nason Medical Center CIA
G. Risk Assessment and Internal Review Process

Within 90 days after the Effective Date, Nason shall develop and implement a centralized annual risk assessment and internal review process to identify and address risks associated with the submission of claims for items and services furnished to Medicare and Medicaid program beneficiaries. The risk assessment and internal review process should include: (1) a process for identifying and prioritizing risks, (2) developing remediation plans in response to those risks, including internal auditing and monitoring of the identified risk areas, and (3) tracking results to assess the effectiveness of the remediation plans. The risk assessment and internal review process should require compliance, legal and department leaders, at least annually, to evaluate and identify risks associated with the submission of claims for items and services furnished to Medicare and Medicaid program beneficiaries and develop and implement specific plans to address and mitigate the identified risks. The risk assessment and internal review work plans shall be developed annually. Nason shall implement the risk assessment and internal review work plans and track the implementation of the work plans. Nason shall maintain the risk assessment and internal review process for the term of the CIA. Copies of any internal audit reports developed pursuant to the risk assessment and internal review process shall be made available to OIG upon request.

H. Disclosure Program

Within 90 days after the Effective Date, Nason shall establish a Disclosure Program that includes a mechanism (e.g., a toll-free compliance telephone line) to enable individuals to disclose, to the Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Nason’s policies, conduct, practices, or procedures with respect to a Federal health care program believed by the individual to be a potential violation of criminal, civil, or administrative law. Nason shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas).

The Disclosure Program shall emphasize a nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she

Nason Medical Center CIA
has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Nason shall conduct an internal review of the allegations set forth in the disclosure and ensure that proper follow-up is conducted.

The Compliance Officer (or designee) shall maintain a disclosure log and shall record each disclosure in the disclosure log within 48 hours of receipt of the disclosure. The disclosure log shall include a summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews.

I. Ineligible Persons

1. Definitions. For purposes of this CIA:

   a. an “Ineligible Person” shall include an individual or entity who:

      i. is currently excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs; or

      ii. has been convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible.

   b. “Exclusion Lists” include:

      i. the HHS/OIG List of Excluded Individuals/Entities (LEIE) (available through the Internet at http://www.oig.hhs.gov); and

      ii. the General Services Administration’s System for Award Management (SAM) (available through the Internet at http://www.sam.gov).

Nason Medical Center CIA
2. **Screening Requirements.** Nason shall ensure that all prospective and current Covered Persons are not Ineligible Persons, by implementing the following screening requirements.

   a. Nason shall screen all prospective Covered Persons against the Exclusion Lists prior to engaging their services and, as part of the hiring or contracting process, shall require such Covered Persons to disclose whether they are Ineligible Persons.

   b. Nason shall screen all Covered Persons against the Exclusion Lists within 90 days after the Effective Date and thereafter shall screen against the LEIE on a monthly basis and screen against SAM on an annual basis.

   c. Nason shall implement a policy requiring all Covered Persons to disclose immediately any debarment, exclusion, suspension, or other event that makes that person an Ineligible Person.

   Nothing in Section III.I affects Nason’s responsibility to refrain from (and liability for) billing Federal health care programs for items or services furnished, ordered, or prescribed by an excluded person. Nason understands that items or services furnished, ordered or prescribed by excluded persons are not payable by Federal health care programs and that Nason may be liable for overpayments and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless of whether Nason meets the requirements of Section III.I.

3. **Removal Requirement.** If Nason has actual notice that a Covered Person has become an Ineligible Person, Nason shall remove such Covered Person from responsibility for, or involvement with, Nason’s business operations related to the Federal health care programs and shall remove such Covered Person from any position for which the Covered Person’s compensation or the items or services furnished, ordered, or prescribed by the Covered Person are paid in whole or part, directly or indirectly, by Federal health care programs or otherwise with Federal funds at least until such time as the Covered Person is reinstated into participation in the Federal health care programs.
4. **Pending Charges and Proposed Exclusions.** If Nason has actual notice that a Covered Person is charged with a criminal offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person’s employment or contract term or during the term of a physician’s or other practitioner’s medical staff privileges, Nason shall take all appropriate actions to ensure that the responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary, patient, or resident, or any claims submitted to any Federal health care program.

J. **Notification of Government Investigation or Legal Proceedings**

Within 30 days after discovery, Nason shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to Nason conducted or brought by a governmental entity or its agents involving an allegation that Nason has committed a crime or has engaged in fraudulent activities. This notification shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding. Nason shall also provide written notice to OIG within 30 days after the resolution of the matter, and shall provide OIG with a description of the findings and/or results of the investigation or proceedings, if any.

K. **Repayment of Overpayments**

1. **Definition of Overpayments.** For purposes of this CIA, an “Overpayment” shall mean the amount of money Nason has received in excess of the amount due and payable under any Federal health care program requirements.

2. **Overpayment Policies and Procedures.** Within 90 days after the Effective Date, Nason shall develop and implement written policies and procedures regarding the identification, quantification and repayment of Overpayments received from any Federal health care program.

3. **Repayment of Overpayments.**

   a. If, at any time, Nason identifies any Overpayment, Nason shall repay the Overpayment to the appropriate payor (e.g., Medicare contractor) within 60 days after identification of the Overpayment and take remedial steps within 90 days after identification (or such additional time as may be agreed to by the payor) to correct the problem, including preventing the
underlying problem and the Overpayment from recurring. If not yet quantified, within 60 days after identification, Nason shall notify the payor of its efforts to quantify the Overpayment amount along with a schedule of when such work is expected to be completed. Notification and repayment to the payor shall be done in accordance with the payor's policies.

b. Notwithstanding the above, notification and repayment of any Overpayment amount that routinely is reconciled or adjusted pursuant to policies and procedures established by the payor should be handled in accordance with such policies and procedures.

I. Reportable Events

1. Definition of Reportable Event. For purposes of this CIA, a “Reportable Event” means anything that involves:

   a. a substantial Overpayment;

   b. a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized;

   c. the employment of or contracting with a Covered Person who is an Ineligible Person as defined by Section III.I.1.a; or

   d. the filing of a bankruptcy petition by Nason.

A Reportable Event may be the result of an isolated event or a series of occurrences.

2. Reporting of Reportable Events. If Nason determines (after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Nason shall notify OIG, in writing, within 30 days after making the determination that the Reportable Event exists.

Nason Medical Center CIA
3. **Reportable Events under Section III.L.1.a.** For Reportable Events under Section III.L.1.a, the report to OIG shall be made within 30 days of the identification of the Overpayment, and shall include:

a. a complete description of all details relevant to the Reportable Event, including, at minimum, the types of claims, transactions or other conduct giving rise to the Reportable Event; the period during which the conduct occurred; and the names of entities and individuals believed to be implicated, including an explanation of their roles in the Reportable Event;

b. the Federal health care programs affected by the Reportable Event;

c. a description of the steps taken by Nason to identify and quantify the Overpayment; and

d. a description of Nason’s actions taken to correct the Reportable Event and prevent it from recurring.

Within 60 days of identification of the Overpayment, Nason shall provide OIG with a copy of the notification and repayment (if quantified) to the payor required in Section III.L.3.

4. **Reportable Events under Section III.L.1.b.** For Reportable Events under Section III.L.1.b, the report to OIG shall include:

a. a complete description of all details relevant to the Reportable Event, including, at a minimum, the types of claims, transactions or other conduct giving rise to the Reportable Event; the period during which the conduct occurred; and the names of entities and individuals believed to be implicated, including an explanation of their roles in the Reportable Event;

b. a statement of the Federal criminal, civil or administrative laws that are probably violated by the Reportable Event;

Nason Medical Center CIA
c. the Federal health care programs affected by the Reportable Event;

d. a description of Nason’s actions taken to correct the Reportable Event and prevent it from recurring; and

e. if the Reportable Event has resulted in an Overpayment, a description of the steps taken by Nason to identify and quantify the Overpayment.

5. **Reportable Events under Section III.L.1.c.** For Reportable Events under Section III.L.1.c, the report to OIG shall include:

a. the identity of the Ineligible Person and the job duties performed by that individual;

b. the dates of the Ineligible Person’s employment or contractual relationship;

c. a description of the Exclusion Lists screening that Nason completed before and/or during the Ineligible Person’s employment or contract and any flaw or breakdown in the Ineligible Person’s screening process that led to the hiring or contracting with the Ineligible Person;

d. a description of how the Reportable Event was discovered; and

e. a description of any corrective action implemented to prevent future employment or contracting with an Ineligible Person.

6. **Reportable Events under Section III.L.1.d.** For Reportable Events under Section III.L.1.d, the report to the OIG shall include documentation of the bankruptcy filing and a description of any Federal health care program authorities implicated.

7. **Reportable Events Involving the Stark Law.** Notwithstanding the reporting requirements outlined above, any Reportable Event that involves only a probable violation of section 1877 of the Social Security
Act, 42 U.S.C. §1395nn (the Stark Law) should be submitted by Nason to the Centers for Medicare & Medicaid Services (CMS) through the self-referral disclosure protocol (SRDP), with a copy to the OIG. The requirements of Section III.K.3 that requires repayment to the payor of any identified Overpayment within 60 days shall not apply to any Overpayment that may result from a probable violation of only the Stark Law that is disclosed to CMS pursuant to the SRDP. If Nason identifies a probable violation of the Stark Law and repays the applicable Overpayment directly to the CMS contractor, then Nason is not required by this Section III.L to submit the Reportable Event to CMS through the SRDP.

IV. SUCCESSOR LIABILITY; CHANGES TO BUSINESS UNITS OR LOCATIONS

A. Sale of Business, Business Unit or Location.

In the event that, after the Effective Date, Nason proposes to sell any or all of its business, business units or locations (whether through a sale of assets, sale of stock, or other type of transaction) that are subject to this CIA, Nason shall notify OIG of the proposed sale at least 30 days prior to the sale of its business, business unit or location. This notification shall include a description of the business, business unit or location to be sold, a brief description of the terms of the sale, and the name and contact information of the prospective purchaser. This CIA shall be binding on the purchaser of the business, business unit or location, unless otherwise determined and agreed to in writing by the OIG.

B. Change or Closure of Business, Business Unit or Location

In the event that, after the Effective Date, Nason changes locations or closes a business, business unit or location related to the furnishing of items or services that may be reimbursed by Federal health care programs, Nason shall notify OIG of this fact as soon as possible, but no later than within 30 days after the date of change or closure of the business, business unit or location.

C. Purchase or Establishment of New Business, Business Unit or Location

In the event that, after the Effective Date, Nason purchases or establishes a new business, business unit or location related to the furnishing of items or services that may be reimbursed by Federal health care programs, Nason shall notify OIG of this fact as soon as possible, but no later than within 30 days after the date of purchase or establishment of the new business, business unit or location.
be reimbursed by Federal health care programs, Nason shall notify OIG at least 30 days 
prior to such purchase or the operation of the new business, business unit or location. 
This notification shall include the address of the new business, business unit or location, 
phone number, fax number, the location’s Medicare and state Medicaid program provider 
number and/or supplier number(s); and the name and address of each Medicare and state 
Medicaid program contractor to which Nason currently submits claims. Each new 
business, business unit or location and all Covered Persons at each new business, 
business unit or location shall be subject to the applicable requirements of this CIA, 
unless otherwise agreed to in writing by the OIG.

V. IMPLEMENTATION AND ANNUAL REPORTS

A. Implementation Report

Within 120 days after the Effective Date, Nason shall submit a written report to 
OIG summarizing the status of its implementation of the requirements of this CIA 
(Implementation Report). The Implementation Report shall, at a minimum, include:

1. the name, address, phone number, and position description of the 
Compliance Officer required by Section III.A, and a summary of other noncompliance 
job responsibilities the Compliance Officer may have;

2. the names and positions of the members of the Compliance 
Committee required by Section III.A;

3. the names of the “Management Committee” members who are responsible for satisfying the “Management Committee’s” compliance obligations described in Section III.A.3;

4. the names and positions of the Certifying Employees required by 
Section III.A.4;

5. a copy of Nason’s Code of Conduct required by Section III.B.1;

6. a summary of all Policies and Procedures required by Section III.B 
copies of the Policies and Procedures shall be made available to OIG upon request);

Nason Medical Center CIA
7. the Training Plan required by Section III.C.1 and a description of the "Management Committee’s" training required by Section III.C.3 (including a summary of the topics covered, the length of the training; and when the training was provided);

8. a description of all efforts taken by Nason to comply with Section III.D.

9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between Nason and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to Nason;

10. a description of the risk assessment and mitigation process required by Section III.G;

11. a description of the Disclosure Program required by Section III.H;

12. a certification that Nason has conducted the screening required by Section III.I regarding Ineligible Persons, or a description of why Nason cannot provide such a certification;

13. a copy of Nason’s policies and procedures regarding the identification, quantification and repayment of Overpayments required by Section III.K;

14. a list of all of Nason’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number(s) and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which Nason currently submits claims;

15. a description of Nason’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business, and any individual owners; and

16. the certifications required by Section V.C.

B. Annual Reports

Nason Medical Center CIA
Nason shall submit to OIG annually a report with respect to the status of, and findings regarding, Nason's compliance activities for each of the five Reporting Periods (Annual Report). Each Annual Report shall include, at a minimum:

1. any change in the identity, position description, or other noncompliance job responsibilities of the Compliance Officer; any change in the membership of the Compliance Committee described in Section III.A, any change in the "Management Committee’s" members who are responsible for satisfying the "Management Committee’s" compliance obligations described in Section III.A.3, and any change in the group of Certifying Employees described in Section III.A.4;

2. the dates of each report made by the Compliance Officer to the Board (written documentation of such reports shall be made available to OIG upon request);

3. the "Management Committee" resolution required by Section III.A.3, and a description of the documents and other materials reviewed by the "Management Committee", as well as any additional steps taken, in its oversight of the compliance program and in support of making the resolution;

4. a summary of any significant changes or amendments to the Code of Conduct or the Policies and Procedures required by Section III.B and the reasons for such changes (e.g., change in contractor policy);

5. a copy of Nason's Training Plan developed under Section III.C and the following information regarding each type of training required by the Training Plan: a description of the training, including a summary of the topics covered; the length of sessions, a schedule of training sessions, a general description of the categories of individuals required to complete the training, and the process by which Nason ensures that all designated employees receive appropriate training. A copy of all training materials and the documentation to support this information shall be made available to OIG upon request.

6. a description of all activities taken to comply with Section III.D;

7. a complete copy of all reports prepared pursuant to Section III.F, along with a copy of the IRO’s engagement letter;

Nason Medical Center CIA
8. Nason’s response to the reports prepared pursuant to Section III.E, along with corrective action plan(s) related to any issues raised by the reports;

9. a summary and description of any and all current and prior engagements and agreements between Nason and the IRO (if different from what was submitted as part of the Implementation Report);

10. a certification from the IRO regarding its professional independence and objectivity with respect to Nason;

11. a description of the risk assessment and internal review process required by Section III.G, a summary of any changes to the process, and a description of the reasons for such changes;

12. a copy of Nason’s internal review work plans, and a list of all reviews completed during the Reporting Period pursuant to Section III.G;

13. a summary of the disclosures in the disclosure log required by Section III.H that relate to Federal health care programs (the complete disclosure log shall be made available to OIG upon request);

14. a certification that Nason has completed the screening required by Section III.I regarding Ineligible Persons;

15. a summary describing any ongoing investigation or legal proceeding required to have been reported pursuant to Section III.J. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding;

16. a description of any changes to the Overpayment policies and procedures required by Section III.K, including the reasons for such changes;

17. a report of the aggregate Overpayments that have been returned to the Federal health care programs. Overpayment amounts shall be broken down into the following categories: outpatient Medicare, Medicaid (report each applicable state separately, if applicable), and other Federal health care programs. Overpayment amounts that are routinely reconciled or adjusted pursuant to policies and procedures established by the payor do not need to be included in this aggregate Overpayment report;

Nason Medical Center CIA
18. a summary of Reportable Events (as defined in Section III.L) identified during the Reporting Period and the status of any corrective action relating to all such Reportable Events;

19. a summary describing any audits conducted during the applicable Reporting Period by a Medicare or state Medicaid program contractor or any government entity or contractor, involving a review of Federal health care program claims, and Nason's response/corrective action plan (including information regarding any Federal health care program refunds) relating to the audit findings;

20. a description of all changes to the most recently provided list of Nason's locations (including addresses) as required by Section V.A.14; the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location's Medicare and state Medicaid program provider number(s) and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which Nason currently submits claims;

21. the certifications required by Section V.C.;

The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report.

C. Certifications

1. Certifying Employees. In each Annual Report, Nason shall include the certifications of Certifying Employees as required by Section III.A.4;

2. Compliance Officer and Chief Executive Officer. The Implementation Report and each Annual Report shall include a certification by the Compliance Officer and Chief Executive Officer that:

   a. to the best of his or her knowledge, except as otherwise described in the report, Nason is in compliance with all of the requirements of this CIA; and

   b. he or she has reviewed the report and has made reasonable inquiry regarding its content and believes that the information in the report is accurate and truthful.

Nason Medical Center CIA
3. **Chief Financial Officer.** The first Annual Report shall include a certification by the Chief Financial Officer that, to the best of his or her knowledge, Nason has complied with its obligations under the Settlement Agreement: (a) not to resubmit to any Federal health care program payors any previously denied claims related to the Covered Conduct addressed in the Settlement Agreement, and not to appeal any such denials of claims; (b) not to charge to or otherwise seek payment from federal or state payors for unallowable costs (as defined in the Settlement Agreement); and (c) to identify and adjust any past charges or claims for unallowable costs.

D. **Designation of Information**

Nason shall clearly identify any portions of its submissions that it believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. § 552. Nason shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA.

**VI. NOTIFICATIONS AND SUBMISSION OF REPORTS**

Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities:

**OIG:**

Administrative and Civil Remedies Branch  
Office of Counsel to the Inspector General  
Office of Inspector General  
U.S. Department of Health and Human Services  
Cohen Building, Room 5527  
330 Independence Avenue, S.W.  
Washington, DC 20201  
Telephone: 202.619.2078  
Facsimile: 202.205.0604

**Nason:**

Nason Medical Center

Nason Medical Center CIA
Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, Nason may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), in addition to a paper copy.

VII. OIG INSPECTION, AUDIT, AND REVIEW RIGHTS

In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized representative(s) may examine and/or request copies of Nason’s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Nason’s locations for the purpose of verifying and evaluating: (a) Nason’s compliance with the terms of this CIA; and (b) Nason’s compliance with the requirements of the Federal health care programs. The documentation described above shall be made available by Nason to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, and/or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may interview any of Nason’s Covered Persons who consent to be interviewed at the individual’s place of business during normal business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. Nason shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. Nason’s Covered Persons may elect to be interviewed with or without a representative of Nason present.

VIII. DOCUMENT AND RECORD RETENTION

Nason shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs and to compliance with this CIA for six years (or longer if otherwise required by law) from the Effective Date.

Nason Medical Center CIA
IX. DISCLOSURES

Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Nason prior to any release by OIG of information submitted by Nason pursuant to its obligations under this CIA and identified upon submission by Nason as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Nason shall have the rights set forth at 45 C.F.R. § 5.65(d).

X. BREACH AND DEFAULT PROVISIONS

Nason is expected to fully and timely comply with all of its CIA obligations.

A. Stipulated Penalties for Failure to Comply with Certain Obligations

As a contractual remedy, Nason and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions.

1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Nason fails to establish and implement any of the following obligations as described in Sections III and IV:

   a. a Compliance Officer;

   b. a Compliance Committee;

   c. the “Management Committee’s” compliance obligations;

   d. the management certification obligations;

   e. a written Code of Conduct;

   f. written Policies and Procedures;

   g. the development and/or implementation of a Training Plan for the training of Covered Persons, Relevant Covered Persons, and “Management Committee” Members;

Nason Medical Center CIA
h. any representation made which does not conform with Nason’s obligations under Section III.D;

i. any provision of imaging services, except x-rays, as required under Section III.D;

j. any provision of services not in compliance with Section III.D;

k. retention of a monitor;

l. retention of an IRO;

m. a risk assessment and mitigation process as required in Section III.G;

n. a Disclosure Program;

o. Ineligible Persons screening and removal requirements;

p. notification of Government investigations or legal proceedings;

q. policies and procedures regarding the repayment of Overpayments;

r. the repayment of Overpayments as required by Section III.K;

s. reporting of Reportable Events; and

t. disclosure of changes to business units or locations.

2. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Nason fails to engage and use an IRO, as required in Section III.F, Appendix A, and Appendix B.

3. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Nason fails to submit the
Implementation Report or any Annual Reports to OIG in accordance with the requirements of Section V by the deadlines for submission.

4. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Nason fails to submit any Claims Review Report in accordance with the requirements of Section III.F and Appendix B.

5. A Stipulated Penalty of $1,500 for each day Nason fails to grant access as required in Section VII. (This Stipulated Penalty shall begin to accrue on the date Nason fails to grant access.)

6. A Stipulated Penalty of $50,000 for each false certification submitted by or on behalf of Nason as part of its Implementation Report, Annual Report, additional documentation to a report (as requested by the OIG), or otherwise required by this CIA.

7. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Nason fails to pay a Monitor, as required in Section III.E.5.

8. A Stipulated Penalty of $2,500 for each day Nason fails to comply fully and adequately with any of its obligations with respect to the Monitor, including, but not limited to, the obligation to adequately and timely respond to any written recommendation of the Monitor, as set forth in Section III.E.6. OIG shall provide notice to Nason stating the specific grounds for its determination that Nason has failed to comply fully and adequately with the CIA obligation(s) at issue and steps Nason shall take to comply with the CIA. (This Stipulated Penalty shall begin to accrue 10 days after Nason receives this notice from OIG of the failure to comply.)

9. A Stipulated Penalty of $1,000 for each day Nason fails to comply fully and adequately with any obligation of this CIA. OIG shall provide notice to Nason stating the specific grounds for its determination that Nason has failed to comply fully and adequately with the CIA obligation(s) at issue and steps Nason shall take to comply with the CIA. (This Stipulated Penalty shall begin to accrue 10 days after Nason receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under Subsections 1-8 of this Section.

Nason Medical Center CIA
B. Timely Written Requests for Extensions

Nason may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this CIA. Notwithstanding any other provision in this Section, if OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Nason fails to meet the revised deadline set by OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until three days after Nason receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a request in writing received by OIG at least five days prior to the date by which any act is due to be performed or any notification or report is due to be filed.

C. Payment of Stipulated Penalties

1. Demand Letter. Upon a finding that Nason has failed to comply with any of the obligations described in Section X.A and after determining that Stipulated Penalties are appropriate, OIG shall notify Nason of: (a) Nason’s failure to comply; and (b) OIG’s exercise of its contractual right to demand payment of the Stipulated Penalties. (This notification shall be referred to as the “Demand Letter.”)

2. Response to Demand Letter. Within 10 days after the receipt of the Demand Letter, Nason shall either: (a) cure the breach to OIG’s satisfaction and pay the applicable Stipulated Penalties or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG’s determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Nason elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until Nason cures, to OIG’s satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this CIA and shall be grounds for exclusion under Section X.D.

3. Form of Payment. Payment of the Stipulated Penalties shall be made by electronic funds transfer to an account specified by OIG in the Demand Letter.

4. Independence from Material Breach Determination. Except as set forth in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s decision that Nason has materially breached
D. Exclusion for Material Breach of this CIA

1. **Definition of Material Breach.** A material breach of this CIA means:
   
a. repeated violations or a flagrant violation of any of the obligations under this CIA, including, but not limited to, the obligations addressed in Section X.A;
   
b. a violation of any obligation under this CIA that has a material impact on the quality of patient care;
   
c. a failure by Nason to report a Reportable Event, take corrective action, or make the appropriate refunds, as required in Section III.L;
   
d. a failure to respond to a Demand Letter concerning the payment of Stipulated Penalties in accordance with Section X.C;
   
e. a failure to engage and use an IRO in accordance with Section III.F, Appendix A, and Appendix B; or
   
f. failure to retain, pay, or use the Monitor, or failure to respond to the recommendations of the Monitor, in accordance with Section III.E.

2. **Notice of Material Breach and Intent to Exclude.** The parties agree that a material breach of this CIA by Nason constitutes an independent basis for Nason’s exclusion from participation in the Federal health care programs. The length of the exclusion shall be in the OIG’s discretion, but not more than five years per material breach. Upon a determination by OIG that Nason has materially breached this CIA and that exclusion is the appropriate remedy, OIG shall notify Nason of: (a) Nason’s material breach; and (b) OIG’s intent to exercise its contractual right to impose exclusion. (This notification shall be referred to as the “Notice of Material Breach and Intent to Exclude.”)
3. **Opportunity to Cure.** Nason shall have 30 days from the date of receipt of the Notice of Material Breach and Intent to Exclude to demonstrate that:

   a. the alleged material breach has been cured; or

   b. the alleged material breach cannot be cured within the 30 day period, but that: (i) Nason has begun to take action to cure the material breach; (ii) Nason is pursuing such action with due diligence; and (iii) Nason has provided to OIG a reasonable timetable for curing the material breach.

4. **Exclusion Letter.** If, at the conclusion of the 30 day period, Nason fails to satisfy the requirements of Section X.D.3, OIG may exclude Nason from participation in the Federal health care programs. OIG shall notify Nason in writing of its determination to exclude Nason. (This letter shall be referred to as the “Exclusion Letter.”) Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of Nason’s receipt of the Exclusion Letter. The exclusion shall have national effect. Reinstatement to program participation is not automatic. After the end of the period of exclusion, Nason may apply for reinstatement by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004.

E. **Dispute Resolution**

1. **Review Rights.** Upon OIG’s delivery to Nason of its Demand Letter or of its Exclusion Letter, and as an agreed-upon contractual remedy for the resolution of disputes arising under this CIA, Nason shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS Departmental Appeals Board (DAB), in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made within 10 days after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. The procedures relating to the filing of a request for a hearing can be found at http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html.
2. **Stipulated Penalties Review.** Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Nason was in full and timely compliance with the obligations of this CIA for which OIG demands payment; and (b) the period of noncompliance. Nason shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an adverse ALJ decision related to Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders Nason to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a decision unless Nason requests review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues its decision.

3. **Exclusion Review.** Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be whether Nason was in material breach of this CIA and, if so, whether:

   a. Nason cured such breach within 30 days of its receipt of the Notice of Material Breach; or

   b. the alleged material breach could not have been cured within the 30-day period, but that, during the 30-day period following Nason’s receipt of the Notice of Material Breach: (i) Nason had begun to take action to cure the material breach; (ii) Nason pursued such action with due diligence; and (iii) Nason provided to OIG a reasonable timetable for curing the material breach.

For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision favorable to OIG, or, if the ALJ rules for Nason, only after a DAB decision in favor of OIG. Nason’s election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to exclude Nason upon the issuance of an ALJ’s decision in favor of OIG. If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that Nason may request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Nason shall waive its right to

Nason Medical Center CIA
any notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Nason, Nason shall be reinstated effective on the date of the original exclusion.

4. **Finality of Decision.** The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any statutes or regulations. Consequently, the parties to this CIA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be considered final for all purposes under this CIA.

XI. **EFFECTIVE AND BINDING AGREEMENT**

Nason and OIG agree as follows:

A. This CIA shall become final and binding on the date the final signature is obtained on the CIA.

B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.

C. OIG may agree to a suspension of Nason’s obligations under this CIA based on a certification by Nason that it is no longer providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Nason is relieved of its CIA obligations, Nason will be required to notify OIG in writing at least 30 days in advance if Nason plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified.

D. The undersigned Nason signatories represent and warrant that they are six authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacities and that they are authorized to execute this CIA.

E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA.

Nason Medical Center CIA
ON BEHALF OF NASON

/Barron Nason/

BARRON NASON
Chief Executive Officer and Manager of
Nason Medical Center

12/22/2014

DATE

Nason Medical Center CIA
ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL
OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

/Robert K. DeConti/

ROBERT K. DECONTI
Assistant Inspector General for Legal Affairs
Office of Inspector General
U.S. Department of Health and Human Services

/Sandra Jean Sands/

SANDRA JEAN SANDS
Senior Counsel
Office of Inspector General
U.S. Department of Health and Human Services
APPENDIX A
INDEPENDENT REVIEW ORGANIZATION

This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.F of the CIA.

A. IRO Engagement

1. Nason shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.9 of the CIA or any additional information submitted by Nason in response to a request by OIG, whichever is later, OIG will notify Nason if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Nason may continue to engage the IRO.

2. If Nason engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, Nason shall submit the information identified in Section V.A.9 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Nason at the request of OIG, whichever is later, OIG will notify Nason if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Nason may continue to engage the IRO.

B. IRO Qualifications

The IRO shall:

1. assign individuals to conduct the Claims Review who have expertise in the billing, coding, reporting, and other requirements of Urgent Care Centers and in the general requirements of the Federal health care program(s) from which Nason seeks reimbursement;

2. assign individuals to design and select the Claims Review sample who are knowledgeable about the appropriate statistical sampling techniques;

3. assign individuals to conduct the coding review portions of the Claims Review who have a nationally recognized coding certification and who have maintained this certification (e.g., completed applicable continuing education requirements); and

4. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis.

C. IRO Responsibilities

The IRO shall:
1. perform each Claims Review in accordance with the specific requirements of the CIA;

2. follow all applicable Medicare, Medicaid and other Federal health care programs, as necessary, rules and reimbursement guidelines in making assessments in the Claims Review;

3. if in doubt of the application of a particular Medicare, Medicaid or other Federal health care programs, as necessary, policy or regulation, request clarification from the appropriate authority (e.g., Medicare contractor);

4. respond to all OIG inquiries in a prompt, objective, and factual manner;

and

5. prepare timely, clear, well-written reports that include all the information required by Appendix B to the CIA.

D. IRO Independence and Objectivity

The IRO must perform the Claims Review in a professionally independent and objective fashion, as defined in the most recent Government Auditing Standards issued by the United States Government Accountability Office.

E. IRO Removal/Termination

1. Nason and IRO. If Nason terminates its IRO or if the IRO withdraws from the engagement during the term of the CIA, Nason must submit a notice explaining its reasons for termination or the reason for withdrawal to OIG no later than 30 days after termination or withdrawal. Nason must engage a new IRO in accordance with Paragraph A of this Appendix and within 60 days of termination or withdrawal of the IRO.

2. OIG Removal of IRO. In the event OIG has reason to believe the IRO does not possess the qualifications described in Paragraph B, is not independent and objective as set forth in Paragraph D, or has failed to carry out its responsibilities as described in Paragraph C, OIG may, at its sole discretion, require Nason to engage a new IRO in accordance with Paragraph A of this Appendix. Nason must engage a new IRO, with approval of the OIG, within 60 days of termination of the IRO.

Prior to requiring Nason to engage a new IRO, OIG shall notify Nason of its intent to do so and provide a written explanation of why OIG believes such a step is necessary. To resolve any concerns raised by OIG, Nason may present additional information regarding the IRO's qualifications, independence or performance of its responsibilities. OIG will attempt in good faith to resolve any differences regarding the IRO with Nason prior to requiring Nason to terminate the IRO. However, the final determination as to whether or not to require Nason to engage a new IRO shall be made at the sole discretion of OIG.
APPENDIX B

CLAIMS REVIEW

A. Claims Review. The IRO shall perform the Claims Review annually to cover each of the five Reporting Periods. The IRO shall perform all components of each Claims Review.

1. Definitions. For the purposes of the Claims Review, the following definitions shall be used:

a. **Overpayment**: The amount of money Nason has received in excess of the amount due and payable under any Federal health care program requirements, as determined by the IRO in connection with the claims reviews performed under this Appendix B, and which shall include any extrapolated Overpayments determined in accordance with Section A.3 of this Appendix B.

b. **Paid Claim**: A claim submitted by Nason and for which Nason has received reimbursement from the Medicare or Medicaid program.

c. **Population**: The Population shall be defined as all Paid Claims during the 12-month period covered by each of the Claims Reviews.

d. **Error Rate**: The Error Rate shall be the percentage of net Overpayments identified in each sample. The net Overpayments shall be calculated by subtracting all underpayments identified in each sample from all gross Overpayments identified in that sample. (Note: Any potential cost settlements or other supplemental payments should not be included in the net Overpayment calculation. Rather, only underpayments identified as part of the Discovery Sample shall be included as part of the net Overpayment calculation.)

   The Error Rate is calculated by dividing the net Overpayment identified in each sample by the total dollar amount associated with the Paid Claims in that sample.

2. **Discovery Samples**. The IRO shall randomly select and review two samples of 200 Paid Claims (Discovery Samples). One sample is for Paid Claims for Personally Performed Services provided by physicians and physician extenders and the other sample is for Paid Claims for Ancillary Services (e.g. all other services) for which Nason was paid. The Paid Claims shall be reviewed based on the supporting documentation available at Nason’s office or under Nason’s control and applicable billing and coding regulations and guidance to determine whether the claim was correctly coded, submitted, and reimbursed.
If the Error Rate (as defined above) for each Discovery Sample is less than 5%, no additional sampling is required, nor is the Systems Review required. (Note: The guidelines listed above do not imply that this is an acceptable error rate. Accordingly, Nason should, as appropriate, further analyze any errors identified in each Discovery Sample. Nason recognizes that OIG or other HHS component, in its discretion and as authorized by statute, regulation, or other appropriate authority may also analyze or review Paid Claims included, or errors identified, in the Discovery Samples or any other segment of the universe.)

3. **Full Sample.** If either Discovery Sample indicates that the Error Rate is 5% or greater, the IRO shall select an additional sample of Paid Claims (Full Sample) using commonly accepted sampling methods. The Paid Claims selected for the Full Sample shall be reviewed based on supporting documentation available at Nason or under Nason’s control and applicable billing and coding regulations and guidance to determine whether the claim was correctly coded, submitted, and reimbursed. For purposes of calculating the size of the Full Sample, the Discovery Sample may serve as the probe sample, if statistically appropriate. Additionally, the IRO may use the Paid Claims sampled as part of the Discovery Sample, and the corresponding findings for those Paid Claims, as part of its Full Sample, if: (1) statistically appropriate and (2) the IRO selects the Full Sample Paid Claims using the seed number generated by the Discovery Sample. The findings of the Full Sample shall be used by the IRO to estimate the actual Overpayment in the Population with a 90% confidence level and with a maximum relative precision of 25% of the point estimate. OIG, in its sole discretion, may refer the findings of the Full Sample (and any related workpapers) received from Nason to the appropriate Federal health care program payor (e.g., Medicare contractor), for appropriate follow-up by that payor.

4. **Systems Review.** If either of Nason’s Discovery Samples identifies an Error Rate of 5% or greater, Nason’s IRO shall also conduct a Systems Review. The Systems Review shall consist of the following:
   
a. a review of Nason’s billing and coding systems and processes relating to claims submitted to Federal health care programs (including, but not limited to, the operation of the billing system, the process by which claims are coded, safeguards to ensure proper coding, claims submission and billing; and procedures to identify and correct inaccurate coding and billing);

b. for each claim in the Discovery Sample and Full Sample that resulted in an Overpayment, the IRO shall review the system(s) and process(es) that generated the claim and identify any problems or weaknesses that may have resulted in the identified Overpayments. The IRO shall provide its observations and recommendations on suggested improvements to the system(s) and the process(es) that generated the claim.

5. **Other Requirements**
a. **Supplemental Materials.** The IRO shall request all documentation and materials required for its review of the Paid Claims selected as part of the Discovery Sample or Full Sample (if applicable), and Nason shall furnish such documentation and materials to the IRO prior to the IRO initiating its review of the Discovery Sample or Full Sample (if applicable). If the IRO accepts any supplemental documentation or materials from Nason after the IRO has completed its initial review of the Discovery Sample or Full Sample (if applicable) (Supplemental Materials), the IRO shall identify in the Claims Review Report the Supplemental Materials, the date the Supplemental Materials were accepted, and the relative weight the IRO gave to the Supplemental Materials in its review. In addition, the IRO shall include a narrative in the Claims Review Report describing the process by which the Supplemental Materials were accepted and the IRO’s reasons for accepting the Supplemental Materials.

b. **Paid Claims without Supporting Documentation.** Any Paid Claim for which Nason cannot produce documentation sufficient to support the Paid Claim shall be considered an error and the total reimbursement received by Nason for such Paid Claim shall be deemed an Overpayment. Replacement sampling for Paid Claims with missing documentation is not permitted.

c. **Use of First Samples Drawn.** For the purposes of all samples (Discovery Sample(s) and Full Sample(s)) discussed in this Appendix, the Paid Claims selected in each first sample shall be used (i.e., it is not permissible to generate more than one list of random samples and then select one for use with the Discovery Sample or Full Sample).

6. **Repayment of Identified Overpayments.** Nason shall repay within 30 days any Overpayment(s) identified in the Discovery Samples, regardless of the Error Rate, and (if applicable) the Full Sample, including the IRO’s estimate of the actual Overpayment in the Population as determined in accordance with Section A.3 above, in accordance with payor refund policies. Nason shall make available to OIG all documentation that reflects the refund of the Overpayment(s) to the payor.

B. **Claims Review Report.** The IRO shall prepare a Claims Review Report as described in this Appendix for each Claims Review performed. The following information shall be included in the Claims Review Report for each Discovery Sample and Full Sample (if applicable).

1. **Claims Review Methodology**

   a. **Claims Review Population.** A description of the Population subject to the Claims Review.
b. **Claims Review Objective.** A clear statement of the objective intended to be achieved by the Claims Review.

c. **Source of Data.** A description of the specific documentation relied upon by the IRO when performing the Claims Review (e.g., medical records, physician orders, certificates of medical necessity, requisition forms, local medical review policies (including title and policy number), CMS program memoranda (including title and issuance number), Medicare carrier or intermediary manual or bulletins (including issue and date), other policies, regulations, or directives).

d. **Review Protocol.** A narrative description of how the Claims Review was conducted and what was evaluated.

e. **Supplemental Materials.** A description of any Supplemental Materials as required by A.5.a., above.

2. **Statistical Sampling Documentation**

a. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.

b. A copy of the statistical software printout(s) estimating how many Paid Claims are to be included in the Full Sample, if applicable.

c. A description or identification of the statistical sampling software package used to select the sample and determine the Full Sample size, if applicable.

3. **Claims Review Findings**

a. **Narrative Results**

i. A description of Nason's billing and coding system(s), including the identification, by position description, of the personnel involved in coding and billing.

ii. A narrative explanation of the IRO's findings and supporting rationale (including reasons for errors, patterns noted, etc.) regarding the Claims Review, including the results of the Discovery Sample, and the results of the Full Sample (if any).

b. **Quantitative Results**

i. Total number and percentage of instances in which the IRO determined that the Paid Claims submitted by Nason (Claim...
Submitted) differed from what should have been the correct claim (Correct Claim), regardless of the effect on the payment.

ii. Total number and percentage of instances in which the Claim Submitted differed from the Correct Claim and in which such difference resulted in an Overpayment to Nason.

iii. Total dollar amount of all Overpayments in the Discovery Samples and the Full Samples (if applicable).

iv. Total dollar amount of Paid Claims included in the Discovery Samples and the Full Samples and the net Overpayment associated with the Discovery Samples and the Full Samples.

v. Error Rate in each of the Discovery Samples and Full Samples.

vi. A spreadsheet of the Claims Review results that includes the following information for each Paid Claim: Federal health care program billed, beneficiary health insurance claim number, date of service, code submitted (e.g., DRG, CPT code, etc.), code reimbursed, allowed amount reimbursed by payor, correct code (as determined by the IRO), correct allowed amount (as determined by the IRO), dollar difference between allowed amount reimbursed by payor and the correct allowed amount.

vii. If a Full Sample is performed, the methodology used by the IRO to estimate the actual Overpayment in the Population and the amount of such Overpayment.

c. Recommendations. The IRO’s report shall include any recommendations for improvements to Nason’s billing and coding system based on the findings of each Claims Review.

4. Systems Review Findings. The IRO shall prepare a Systems Review Report based on the Systems Review performed (if applicable) that shall include the IRO’s observations, findings, and recommendations regarding:

a. the strengths and weaknesses in Nason’s billing systems and processes;

b. the strengths and weaknesses in Nason’s coding systems and processes; and

c. possible improvements to Nason’s billing and coding systems and processes to address the specific problems or weaknesses that resulted in the identified Overpayments.
5. **Credentials.** The names and credentials of the individuals who: (1) designed the statistical sampling procedures and the review methodology utilized for the Claims Review and (2) performed the Claims Review.